



Published in final edited form as:

*J Eur Acad Dermatol Venereol*. 2010 August ; 24(8): 967–969. doi:10.1111/j.1468-3083.2010.03575.x.

## A novel mutation in the cathepsin C gene in a Pakistani family with Papillon-Lefevre Syndrome

T Cheng<sup>1,¶</sup>, M Kurban<sup>1,¶</sup>, M Wajid<sup>1</sup>, M Kiuru<sup>1</sup>, Y Shimomura<sup>1</sup>, and AM Christiano<sup>1,2</sup>

<sup>1</sup>Department of Dermatology, Columbia University, New York, New York

<sup>2</sup>Department of Genetics & Development, Columbia University, New York, New York

### Abstract

Papillon-Lefevre syndrome (PLS; OMIM 245000) is an autosomal recessive disease caused by cathepsin C (*CTSC*) gene and is clinically characterized by palmoplantar keratoderma, psoriasiform lesion over the extensor surfaces and gingivitis followed by teeth loss. *CTSC* gene is known to be expressed in several tissues including the skin and immune system. In the skin *CTSC* is thought to play a role in differentiation and desquamation. In the immune system it activates serine proteases. Here we investigated a patient from Pakistan with features of PLS and determined a novel deletion mutation designated c.21delG (Leu7PhefsX57) in exon 1 of the *CTSC* gene, that most likely results in absent *CTSC* protein, further extending the spectrum of mutations in the *CTSC* gene.

### Keywords

Papillon-Lefevre syndrome; Cathepsin C; Palmoplantar keratoderma; Gingivitis

---

Papillon Lefevre syndrome (PLS; OMIM 245000), is a rare autosomal recessive keratoderma affecting males and females equally and caused by mutations in the cathepsin C (*CTSC*) gene, GeneBank accession number(NM\_001814.4), located on chromosome 11q14.1

*CTSC* is a lysosomal enzyme expressed in several tissues including the skin, where it is thought to play a major role in epithelial differentiation and desquamation via activation of serine proteases.<sup>2</sup> Thus, mutations in *CTSC* gene is expected to result in a hyperproliferative state, such as observed in the palms and soles of patients with PLS. Moreover, abnormal epithelial differentiation can affect the region adhering the gingiva to the tooth surface, compromising the defense mechanical barrier against pathogens and leading to recurrent gingivitis and loss of teeth with time.<sup>2</sup> *CTSC* is also highly expressed in the immune cells including both the myeloid and lymphoid lineages. These proteases have major roles in the phagocytic destruction of bacteria and activation of cytokines and chemokines. Surprisingly, patients with PLS do not present with any immune dysfunction, suggesting that other pathways, can compensate for the *CTSC* gene in the immune cells. This is in contrast to patients with Chediak-Higashi syndrome, which is also caused by a lysosomal enzyme

---

**Address for Correspondence:** Angela M. Christiano, Ph.D. Department of Dermatology Columbia University College of Physicians & Surgeons 630 West 168th Street VC-1526 New York, New York 10032 Phone: 212-305-9565 Fax: 212-305-7391 amc65@columbia.edu.

<sup>¶</sup>Authors contributed equally to the work

Conflict of interest:None.

defect and characterized by recurrent gingivitis and tooth loss, where patients usually die early secondary to severe immunodeficiency.<sup>3, 4</sup>

To date, more than 50 mutations (Fig.1) have been reported in the *CTSC* gene leading to PLS. Here, we report a novel mutation in the *CTSC*, leading to a mild skin phenotype in a Pakistani patient.

A 35 year old Pakistani individual, son of consanguineous parents, presented to us with several years history of skin thickening involving the palms and soles. He also reported having had two episodes of severe gingivitis, the first at 4 years of age and the second at 14 years with subsequent loss of teeth. Patient reported having a brother and a sister with the same features. On physical examination, we observed mild palmoplantar keratoderma affecting mainly the pressure areas (Fig.2a,b). No psoriasiform lesions were seen over the elbows or the knees. Postaxial polydactyly in the left hand was noted. Oral examination revealed loss of most of his teeth (Fig.2c). The patient was otherwise healthy. We collected peripheral blood sample from patient in EDTA-containing tubes (under institutional approval and in adherence to the Declaration of Helsinki Principles). Genomic DNA was isolated from the sample according to standard techniques. All exons of the *CTSC* gene with adjacent sequences of exon-intron borders were amplified by PCR with primers and conditions described previously.<sup>2</sup> The amplified PCR products were directly sequenced in an ABI Prism 310 Automated Sequencer, using the ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems). We detected a homozygous deletion mutation in exon 1, designated c.21delG, leading to a frameshift and premature termination codon (PTC) (p.Leu7PhefsX57) (Fig.2d). Screening assays with the restriction enzyme *Mwo*I in 100 control individuals from the same population validated the mutation (data not shown).

PLS usually manifests in the first two to three years of life. Clinically, it presents with palmoplantar hyperkeratosis and transgrediens spread with the soles being more extensively involved.<sup>1</sup> Psoriasiform lesions may also develop over the elbows, knees, and knuckles.<sup>2</sup> This is followed later on by periodontitis and gingivitis with subsequent loss of primary and permanent teeth.<sup>1</sup> Patients typically report two episodes of gingivitis, the first one being at 3 years of age leading to primary teeth loss at the age of 5 years.<sup>5</sup> This is followed by a period of remission until the age of 15 years, when a second episode of gingivitis occur, leading to the loss of the permanent teeth.<sup>6</sup> Although patients with PLS are immunocompetent, there is one report of a patient developing an internal fatal abscess,<sup>7</sup> but this could be unrelated to his primary condition. It is worth noting that Japanese patients might be at an increased risk of developing melanomas at the sites of keratoderma.<sup>8</sup>

Here we detected a novel deletion mutation, c.21delG (p.Leu7PhefsX57), in exon 1 of the *CTSC* gene. To date, no deletion mutations have been reported in exon1, and no deletion mutations have been found in the Pakistani population. Mutations in exon1 including nonsense mutations<sup>9, 10</sup> did not show more severe phenotypes than other mutations occurring in different exons. This suggests that there is no genotype-phenotype correlation for mutations in *CTSC* gene.<sup>11</sup> The mutation c.21delG occurred in the N-terminal signaling peptide sequences and is predicted to cause a frameshift and a PTC (p.Leu7PhefsX57). This mutation is expected to lead to the degradation of the mRNA through nonsense mediated mRNA decay or less likely to generate a truncated protein that is nonfunctional. Clinically, our patient had mild palmoplantar keratoderma with teeth loss. The mild palmoplantar involvement and the lack of the psoriasiform lesions over the extensor areas, suggest that the disease is heterogenous in the skin. Several factors may contribute to the disease modification including environmental factors and also genetic factors. There is a variant of late onset PLS that lacks the *CTSC* mutation<sup>12</sup>, suggesting that other genes might have

similar functions to the CTSC gene in the skin and therefore compensating for its absence. This might explain for instance, why our patient despite having a null mutation in the CTSC gene still shows a mild cutaneous phenotype. The common denominators among the patients with PLS are gingivitis and tooth loss, therefore we suggest investigating patients presenting with only severe gingivitis especially in the setting of a positive family history of gingivitis for CTSC gene mutations as the possibility of having only gingival symptoms without cutaneous manifestations may be likely.


In conclusion, we have detected a novel deletion mutation the CTSC gene, extending the spectrum of mutations in the CTSC gene.

## Acknowledgments


We gratefully acknowledge the families for having participated in this study. We also thank Helen Lam for expert technical assistance. This study was supported in part by a research career development award from the Dermatology Foundation (YS) and by USPHS NIH grant from NIH/NIAMS ROI AR44924 (to A.M.C.)

## References

1. Canger EM, Celenk P, Devrim I, Yenisey M, Gunhan O. Intraoral findings of Papillon-LeFevre syndrome. *J Dent Child*. 2008; 75(1):99–103.
2. Toomes C, James J, Wood AJ, et al. Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. *Nat Genet*. 1999; 23(4):421–424. [PubMed: 10581027]
3. Fukai K, Oh J, Karim MA, et al. Homozygosity mapping of the gene for Chediak-Higashi syndrome to chromosome 1q42-q44 in a segment of conserved synteny that includes the mouse beige locus (bg). *Am J Hum Genet*. 1996; 59(3):620–624. [PubMed: 8751863]
4. Karim MA, Nagle DL, Kandil HH, et al. Mutations in the Chediak-Higashi syndrome gene (CHS1) indicate requirement for the complete 3801 amino acid CHS protein. *Hum Mol Genet*. 1997; 6(7): 1087–1089. [PubMed: 9215679]
5. Lundgren T, Renvert S. Periodontal treatment of patients with Papillon-Lefèvre syndrome: a 3-year follow-up. *J Clin Periodontol*. 2004; 31(11):933–938. [PubMed: 15491306]
6. Fardal O, Drangsholt E, Olsen I. Palmar plantar keratosis and unusual periodontal findings: Observations from a family of 4 members. *J Clin Periodontol*. 1998; 25(2):181–184. [PubMed: 9495618]
7. Pham CT, Ivanovich JL, Raptis SZ, Zehnbauser B, Ley TJ. Papillon-Lefèvre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C/dipeptidyl peptidase I deficiency in humans. *J Immunol*. 2004; 173(12):7277–7281. [PubMed: 15585850]
8. Nakajima K, Nakano H, Takiyoshi N, et al. Papillon-Lefèvre syndrome and malignant melanoma: A high incidence of melanoma development in Japanese palmoplantar keratoderma patients. *Dermatology*. 2008; 217(1):58–62. [PubMed: 18401176]
9. Lefèvre C, Blanchet-Bardon C, Jobard F, et al. Novel point mutations, deletions, and polymorphisms in the cathepsin C gene in nine families from Europe and North Africa with Papillon-Lefèvre syndrome. *J Invest Dermatol*. 2001; 117(6):1657–1661. [PubMed: 11886537]
10. Selvaraju V, Markandaya M, Prasad PV, et al. Mutation analysis of the cathepsin C gene in Indian families with Papillon-Lefèvre syndrome. *BMC Med Genet*. 2003; 4:5. [PubMed: 12857359]
11. Noack B, Görgens H, Hempel U, et al. Cathepsin C gene variants in aggressive periodontitis. *J Dent Res*. 2008; 87(10):958–63. [PubMed: 18809751]
12. Pilger U, Hennies HC, Truschnegg A, Aberer E. Late-onset Papillon-Lefèvre syndrome without alteration of the cathepsin C gene. *J Am Acad Dermatol*. 2003; 49(5 Suppl):S240–243. [PubMed: 14576640]



**Figure1.** *CTSC* gene consists of 7 exons and 463 codons. To date, 55 different mutations have been detected in the *Cathepsin C* gene. (The numbers in the boxes indicate exons and numbers outside the boxes indicates introns. Red color indicates the region containing the signal peptide. The blue color indicates the dipeptidyl-peptidase 1 exclusion domain chain containing region. The white color indicates the propeptide chain region. The green color indicates the dipeptidyl-peptidase 1 heavy chain containing region. The yellow color indicates the dipeptidyl-peptidase 1 light chain containing region).



**Figure 2.**  
a,b) Palmoplantar keratoderma affecting mainly the pressure regions in a man with PLS. c) Prominent tooth loss secondary to gingivitis occurring at 14 years of age. d) A deletion mutation designated c.21delG (p.Leu7PhefsX57) in the *CTSC* gene in the affected individual. The deleted nucleotide is boxed.